Unichem Laboratories Limited
All news and filings related to Unichem Laboratories Limited.
View all news & filings- Medium impact
Unichem Laboratories Receives Appellate Order on Tax Dispute, Penalty Amounting to ₹87 Crore
Unichem Laboratories received an appellate order on a tax dispute. The order disallowed a penalty of ₹87.07 crore and interest of ₹6.59 crore. The company believes there will be no material financial impact and plans to appeal the order.
Read the summary - Low impact
Unichem Laboratories Extends ESOP Exercise Period for 375,000 Options
Unichem Laboratories has extended the exercise period for 375,000 employee stock options under its 2018 scheme. The extension affects 250,000 options from the first tranche (vested July 1, 2024) and 125,000 from the second tranche (vested May 1, 2025). The revised exercise period for both is now March 31, 2027.
Read the summary - Low impact
Unichem Laboratories: No Company Comment on Volume Spurt, Cites Market Driven Activity
Unichem Laboratories Limited clarified a recent spurt in trading volume, stating it is market-driven with no company comment. The company confirmed adherence to SEBI disclosure regulations.
Read the summary - Low impact
Unichem Laboratories Ltd: 63rd AGM held on Aug 11, 2026, approves all resolutions.
Unichem Laboratories Limited held its 63rd AGM on August 11, 2026, passing all resolutions. Key approvals included financial statements, re-appointment of Pabitrakumar Bhattacharyya as MD & CEO, and cost auditor remuneration. Voting was conducted via remote e-voting and at the AGM through video conference.
Read the summary - Medium impact
Unichem Labs Q1FY27 Consolidated Income at ₹632.62 Cr, Net Profit ₹41.47 Cr
Unichem Laboratories Limited reported Q1FY27 consolidated results with total income at ₹632.62 crore and net profit at ₹41.47 crore. Standalone profit after tax was ₹5.53 crore. The company also settled a Euro 19.55 million fine with the EU.
Read the summary - Low impact
Unichem Laboratories holds 63rd AGM on Aug 11, 2026, approves financial statements.
Unichem Laboratories Limited conducted its 63rd Annual General Meeting on August 11, 2026. The meeting approved audited standalone and consolidated financial statements for the year ended March 31, 2026. Key decisions included the re-appointment of Mr. Pabitrakumar Bhattacharyya as Managing Director and CEO.
Read the summary - Medium impact
Unichem Labs Q1 FY27 Results: Consolidated Profit at ₹41.47 Cr, Revenue at ₹632.62 Cr
Unichem Laboratories reported Q1 FY27 results. Consolidated profit after tax was ₹41.47 crore on revenue of ₹632.62 crore. Standalone profit after tax was ₹5.53 crore on revenue of ₹366.27 crore. The company invested ₹0.76 crore in its China subsidiary. Results approved by the board on August 11, 2026.
Read the summary - Low impact
Unichem Laboratories Limited Partially Wins GST Appeal, Demand Reduced to ₹10.59 Lakhs
Unichem Laboratories Limited's appeal for GSTR TRAN 1 credit has been partially allowed by the Additional Commissioner, CGST (Appeals), Dehradun. The demand has been reduced to ₹10,59,354/- plus interest. The company does not anticipate a material financial or operational impact and plans to file a further appeal.
Read the summary - Low impact
Unichem Laboratories Promoters Declare No Encumbrance on Shares for FY26
Ipca Laboratories Limited, as a promoter of Unichem Laboratories Limited, declared no encumbrance on its equity shares for the financial year ended March 31, 2026. This is in compliance with SEBI Takeover Regulations.
Read the summary - Low impact
Unichem Laboratories clarifies price movement, cites market driven factors
Unichem Laboratories Limited clarified a significant price movement in its securities, attributing it to market-driven factors. The company confirmed compliance with SEBI disclosure regulations and stated it is unaware of any undisclosed material information contributing to the price surge.
Read the summary - Low impact
Unichem Laboratories Limited Announces 63rd AGM on August 11, 2026
Unichem Laboratories Limited will hold its 63rd AGM on August 11, 2026, via VC/OAVM. Shareholders can access the FY25-26 Annual Report online. The company also urged shareholders to update KYC details as per SEBI mandates.
Read the summary - Low impact
Unichem Laboratories Ltd. publishes newspaper notice for 63rd AGM
Unichem Laboratories Limited announced its 63rd AGM on August 11, 2026, to be held via VC/OAVM. E-voting details and the Annual Report are available online. The company provided a newspaper notice on July 4, 2026, detailing the AGM procedures and e-voting timelines, with a book closure from August 3-10, 2026.
Read the summary - Medium impact
Unichem Laboratories to hold 63rd AGM on August 11, 2026
Unichem Laboratories will hold its 63rd AGM on August 11, 2026, via VC/OAVM. The agenda includes approving FY26 financial statements and re-appointing Mr. Pabitrakumar Bhattacharyya as MD & CEO for three years from August 10, 2026. His remuneration includes ₹20 lakh/month basic salary and other benefits. The AGM will also ratify the appointment of cost auditors for FY27 at ₹6 lakh.
Read the summary - Low impact
Unichem Laboratories Releases Business Responsibility and Sustainability Report for FY26
Unichem Laboratories has released its Business Responsibility and Sustainability Report for FY25-26. The report covers the company's operations, sustainability initiatives, and ESG disclosures. It details product manufacturing, global market presence with exports forming 97.6% of FY26 turnover, and employee welfare programs.
Read the summary - Low impact
Unichem Laboratories: Trading Window Closed from July 1 for Q1 FY27 Results
Unichem Laboratories will close its trading window from July 1, 2026. The window will reopen 48 hours after the financial results for the quarter ended June 30, 2026, are announced, in compliance with SEBI regulations.
Read the summary - Low impact
Unichem Laboratories: AGM on Aug 11, 2026; Public Notice on Shifting Registered Office
Unichem Laboratories will hold its 63rd AGM on August 11, 2026, via video conference. The company is also seeking approval to shift its registered office jurisdiction from ROC Mumbai-I to ROC Mumbai-II. Shareholders with unclaimed dividends from FY 2018-19 must claim them by August 28, 2026, to avoid transfer to IEPF.
Read the summary - Low impact
Unichem Laboratories: Increase in Volume is Market Driven, No Comment
Unichem Laboratories Limited clarified to NSE that the significant increase in its securities' trading volume is market-driven. The company confirmed it has made all timely disclosures as per SEBI regulations and will continue to do so.
Read the summary - Low impact
Unichem Laboratories to hold 63rd AGM on August 11, 2026 via Video Conference
Unichem Laboratories will hold its 63rd Annual General Meeting on August 11, 2026, via video conference. The cut-off date for shareholder voting eligibility is August 4, 2026.
Read the summary - Low impact
Unichem Labs to Transfer Unclaimed Dividend Shares to IEPF by August 16, 2026
Unichem Laboratories will transfer shares with unclaimed dividends from FY 2018-19 to the IEPF Authority. Shareholders must claim their dividends by August 16, 2026, to retain their shares. Notices have been sent and published.
Read the summary - Low impact
Unichem Laboratories Notifies Transfer of Equity Shares and Unclaimed Dividend to IEPF
Unichem Laboratories is transferring unclaimed equity shares and dividends to the IEPF by September 1, 2026, for the 2018-19 unclaimed final dividend. Shareholders must respond by August 16, 2026, to avoid transfer. Duplicate share certificates will be issued for physical shares.
Read the summary - Low impact
Unichem Laboratories Q4 FY26 Results Published in Newspapers
Unichem Laboratories published its Q4 FY26 results on May 23, 2026. Consolidated Q4 income was ₹575.12 crore with ₹18.79 crore net profit. Full-year consolidated income reached ₹2,201.85 crore with ₹57.80 crore net profit. Standalone Q4 income was ₹356.24 crore with ₹10.91 crore net profit.
Read the summary - Medium impact
Unichem Labs Appoints P. Bhattacharyya as MD & CEO; Approves FY26 Results
Unichem Laboratories Limited redesignated Pabitrakumar Bhattacharyya as MD & CEO and re-appointed him for three years from August 10, 2026. The company reported consolidated revenue of ₹575.12 crore and profit after tax of ₹10.91 crore for Q4 FY26. Full-year consolidated revenue was ₹2,201.85 crore with a profit after tax of ₹252.84 crore.
Read the summary - Low impact
Unichem Laboratories Promoters Declare No Encumbrance on Shares for FY26
Ipca Laboratories Limited, a promoter of Unichem Laboratories Limited, declared no encumbrance on shares held in Unichem for FY26. This declaration is in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Read the summary - Low impact
Unichem Pharma USA Recalls Buspirone Hydrochloride Tablets in US
Unichem Pharmaceuticals (USA), Inc. has voluntarily recalled Buspirone Hydrochloride Tablets, USP (5 mg, 500 count bottles) in the USA due to an out-of-specification assay result. No adverse events have been reported to date. The company prioritizes patient safety and product quality.
Read the summary - Medium impact
Unichem Laboratories' ₹180 Cr Bank Facilities Rating Reaffirmed at ICRA A+
ICRA has reaffirmed the [ICRA] A+ rating for Unichem Laboratories' ₹180 crore bank facilities. This rating indicates a stable financial outlook for the company's debt instruments.
Read the summary - Low impact
Unichem Labs: Compliance Certificate for Q4 FY26 Under SEBI Regulations
Unichem Laboratories Limited submitted a compliance certificate for the quarter ended March 31, 2026. The certificate, issued by Link Intime India Pvt. Ltd., confirms adherence to SEBI (Depositories and Participants) Regulations, 2018, regarding the processing of dematerialised securities.
Read the summary - Low impact
Unichem Laboratories Promoter Group Reports No Share Encumbrance for FY26
Unichem Laboratories Promoter and Promoter Group confirm no shares were encumbered during the financial year ended March 31, 2026. This disclosure is made as per SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Read the summary - Medium impact
Unichem Labs Shareholders Approve Director Appointment and Related Party Transactions
Unichem Laboratories Limited shareholders approved the appointment of Dr. Swati Patankar as an Independent Director and material related party transactions. The voting concluded on March 27, 2026, with all resolutions passing via postal ballot and remote e-voting.
Read the summary - Low impact
Unichem Laboratories: Trading Window Closed for FY26 Year-End Results
Unichem Laboratories will close its trading window from April 1, 2026, for designated persons and insiders. The window will reopen 48 hours after the company releases its financial results for the quarter and year ended March 31, 2026.
Read the summary - Low impact
Unichem Labs: Independent Director Mrs. Priti Puri's Term Ends March 20, 2026
Mrs. Priti Puri's term as Independent Director at Unichem Laboratories Limited concludes on March 20, 2026. The Board acknowledged her contributions. The revised board composition, effective March 21, 2026, includes Dr. Prakash Mody as Chairperson and other existing directors.
Read the summary - Low impact
Unichem Laboratories Announces Newspaper Publication for Postal Ballot Notice
Unichem Laboratories Limited published a newspaper notice on February 26, 2026, regarding a Postal Ballot Notice and e-Voting. This follows a previous communication on February 25, 2026, and complies with Section 110 of the Companies Act, 2013.
Read the summary - Medium impact
Unichem Laboratories Seeks Shareholder Approval for Director Appointment and Related Party Transactions
Unichem Laboratories is seeking shareholder approval for the appointment of Dr. Swati Patankar as an Independent Director for five years. Shareholders will also vote on related party transactions: up to ₹400 crore between Ipca Laboratories and Unichem USA, and up to ₹1,600 crore between Unichem and Unichem USA for FY 2026-2027. E-voting is open from February 26 to March 27, 2026.
Read the summary - Low impact
Unichem Laboratories receives order for ₹1.01 Crore from State Tax Authority
Unichem Laboratories received an order from the Deputy Commissioner of State Tax, Appeals Bandra division, Mumbai. The order disallows ₹49.35 lakh ITC for FY19, resulting in a total payable amount of ₹1.01 crore, including interest and penalty. The company believes there will be no material impact and plans to appeal.
Read the summary - Low impact
Unichem Laboratories Q3FY26 Financial Results Published in Newspapers
Unichem Laboratories published its financial results for Q3FY26 on February 6, 2026. The company also reported a court order attaching property due to a debt of ₹88,50,751, with debtors required to pay within 60 days.
Read the summary - Medium impact
Unichem Labs: Q3 FY26 Results & Appoints Dr. Swati Patankar as Independent Director
Unichem Laboratories reported Q3 FY26 results with consolidated revenue at ₹521.17 crore and profit after tax at ₹264.29 crore. Standalone revenue was ₹314.90 crore, with profit after tax at ₹216.11 crore. The company also appointed Dr. (Ms.) Swati Patankar as Non-Executive Independent Director for five years, effective February 5, 2026.
Read the summary - Medium impact
Unichem Labs Appoints Dr. Swati Patankar as Independent Director, Q3 FY26 Results Approved
Unichem Laboratories approved Q3 FY26 results. Consolidated revenue was ₹521.17 crore, with profit after tax at ₹264.29 crore. Standalone revenue was ₹314.90 crore, with profit after tax at ₹216.11 crore. Dr. Swati Patankar was appointed as Non-Executive Independent Director for five years, effective February 5, 2026.
Read the summary - Medium impact
Unichem Laboratories Kolhapur API Facility Undergoes USFDA Inspection
Unichem Laboratories' Kolhapur API facility was inspected by the USFDA from January 27 to February 2, 2026. The inspection resulted in five procedural observations, with no data integrity issues. The company will submit its response within 15 days.
Read the summary - Medium impact
Unichem Pharma USA Recalls Doxazosin and Bisoprolol Tablets in USA
Unichem Laboratories' US subsidiary is voluntarily recalling Doxazosin Tablets (4mg) for appearance defects and Bisoprolol Fumarate/Hydrochlorothiazide Tablets (2.5mg/6.25mg) for impurity specification issues. No adverse events have been reported to date. The company prioritizes patient safety and product quality.
Read the summary - Low impact
Unichem Laboratories Submits Final Report on Re-lodgement of Physical Share Transfer Requests
Unichem Laboratories Limited submitted a final report on the re-lodgement of physical share transfer requests as of January 6, 2026. The report was received from its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, in compliance with SEBI guidelines.
Read the summary - Low impact
Unichem Laboratories: Compliance Certificate for Q3 FY26 Filed
Unichem Laboratories Limited has filed its compliance certificate for the quarter ended December 31, 2025. The certificate from MUFG Intime India Pvt. Ltd. confirms adherence to SEBI (Depositories and Participants) Regulations, 2018. It details the processing of dematerialised securities and updates to the register of members.
Read the summary - Low impact
Unichem Labs: Trading Window Closed from Jan 1, 2026 for Q3 FY26 Results
Unichem Laboratories Limited will close its trading window from January 1, 2026. This closure is in effect for designated persons, directors, and their immediate relatives. The window will reopen 48 hours after the announcement of financial results for the quarter and nine months ended December 31, 2025.
Read the summary - Low impact
Unichem Laboratories Files 5th Report on Re-lodgement of Physical Share Transfer Requests
Unichem Laboratories Limited submitted its 5th report on the re-lodgement of physical share transfer requests for the month ending November 30, 2025. This filing is in compliance with a SEBI circular dated July 2, 2025.
Read the summary - Low impact
Re-lodgement of Transfer Requests of Physical Shares
Unichem Laboratories Limited received a report regarding the re-lodgement of transfer requests of physical shares for October 2025 from MUFG Intime India Private Limited, in compliance with SEBI guidelines.
Read the summary - Medium impact
Unichem Laboratories Approves Unaudited Financial Results for Q2 & H1 Ended Sep 25
Unichem Laboratories' board approves Q2 and H1 FY26 unaudited financial results on November 11, 2025, showcasing consolidated revenue of ₹578.96 crore for the quarter and ₹1,105.56 crore for the half-year.
Read the summary - Medium impact
Unichem Laboratories Announces Financial Results for Quarter Ended Sep 30, 2025
Unichem Labs announces results for quarter ended September 30, 2025. Consolidated total income from operations at ₹578.96 crore. Net loss before tax ₹10.82 crore and after tax ₹11.89 crore.
Read the summary - Low impact
Unichem Laboratories Board approves Q2 and H1 FY26 unaudited standalone and consolidated financial results
Unichem Laboratories' Board approved unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2025 in a meeting held on 11th November 2025.
Read the summary - High impact
Unichem Laboratories Pays Euro 16.75 Million Fine to European Commission
Unichem Laboratories paid a fine of Euro 16.75 million (₹149.79 crore) to the European Commission related to the Perindopril drug matter, resolving a long-standing regulatory issue.
Read the summary - Low impact
Unichem Laboratories Submits 3rd Report on Physical Share Transfer Re-lodgements
Unichem Laboratories submitted its third report on re-lodgement of physical share transfer requests for September 2025, as per SEBI circular. The report, dated October 10, 2025, was provided by MUFG Intime India Private Limited.
Read the summary - Low impact
Compliance Certificate under SEBI Regulations for Quarter Ended Sep 30, 2025
Unichem Laboratories submits compliance certificate under SEBI regulations for the quarter ended September 30, 2025, as confirmed by MUFG Intime India Private Limited.
Read the summary - Low impact
Unichem Laboratories announces change in RTA's investor email address
Unichem Laboratories announced a change in MUFG Intime India Private Limited's investor email to Investor.helpdesk@in.mpms.mufg.com, effective October 1, 2025. Other contact details are unchanged.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio